COVID-19 Vaccination May Provoke Intracranial Hypertension

Abstract

In parallel to the spread of the novel severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), there has been the growing recognition that active SARS-CoV-2 infection has the potential to effect both the peripheral and central nervous systems. When it comes to the SARS-CoV-2 vaccine, however, reporting has been more uncertain. As the vaccination rate has risen, we have seen a rise in rare neurological complications thought to be associated with the vaccination including acute transverse myelitis, Guillain–Barre syndrome, optic neuritis, and Tolosa–Hunt syndrome. The Centers for Disease Control and Prevention (CDC) estimates 98 confirmed cases of Guillain–Barre syndrome out of 12.6 million doses. Given the initial age limits of vaccination eligibility, most reports have been limited to the adult population. Here, we report a case of intracranial hypertension (IH), evolving to fulminant IH in a healthy female after receiving the SARS-CoV-2 vaccine. While elevated intracranial pressure has been reported in the context of active SARS-CoV-2 infections and postinfection multisystem inflammatory syndrome (MIS-C), this is the first reported case of pediatric IH after vaccination alone.

Keywords

COVID-19 - vaccine - intracranial hypertension - ophthalmoplegia - VP shunt

Authors' Contributions

A.E.M.-Z.: study concept and design and drafting manuscript.

R.F.: study concept and designand revising manuscript.

G.O.: figure interpretation, contributed figures, and revising manuscript.

F.A.: study concept and design, revising manuscript, and final approval.

All authors accept responsibility for conduct of the research.

Publikationsverlauf

Eingereicht: 26. November 2021

Angenommen: 12. April 2022

Artikel online veröffentlicht:
18. August 2022

• References

• 1 Totuk OMG, Aldroubı N, Aykan U. A case of bilateral fourth nerve palsy associated with pseudotumor cerebri syndrome. Arq Bras Oftalmol 2019; 82 (04) 332-335
• 2 Silva MTT, Lima MA, Torezani G. et al. Isolated intracranial hypertension associated with COVID-19. Cephalalgia 2020; 40 (13) 1452-1458
• 3 Markey KA, Mollan SP, Jensen RH, Sinclair AJ. Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol 2016; 15 (01) 78-91
• 4 Aylward SC, Reem RE. Pediatric intracranial hypertension. Pediatr Neurol 2017; 66: 32-43
• 5 Abbasi HN, Brady AJ, Cooper SA. Fulminant idiopathic intracranial hypertension with malignant systemic hypertension-a case report. Neuroophthalmology 2013; 37 (03) 120-123
• 6 Thambisetty M, Lavin PJ, Newman NJ, Biousse V. Fulminant idiopathic intracranial hypertension. Neurology 2007; 68 (03) 229-232
• 7 De Simone R, Ranieri A, Sansone M. et al. Dural sinus collapsibility, idiopathic intracranial hypertension, and the pathogenesis of chronic migraine. Neurol Sci 2019; 40 (Suppl. 01) 59-70
• 8 Krueger MB, Montenegro RC, de Araújo Coimbra PP. et al. A wide spectrum of neurological manifestations in pediatrics patients with the COVID-19 infection: a case series. J Neurovirol 2021; 27 (05) 782-786
• 9 Khalid MF, Micieli JA. Idiopathic intracranial hypertension associated with SARS-CoV-2 B.1.1.7 variant of concern. Can J Neurol Sci 2021; 1,2: 1-2
• 10 Verkuil LD, Liu GT, Brahma VL, Avery RA. Pseudotumor cerebri syndrome associated with MIS-C: a case report. Lancet 2020; 396 (10250): 532
• 11 Baccarella A, Linder A, Spencer R. et al. Increased intracranial pressure in the setting of multisystem inflammatory syndrome in children, associated with COVID-19. Pediatr Neurol 2021; 115: 48-49
• 12 Noro F, Cardoso FM, Marchiori E. COVID-19 and benign intracranial hypertension: a case report. Rev Soc Bras Med Trop 2020; 53: e20200325
• 13 Sundholm A, Burkill S, Waldenlind E, Bahmanyar S, Nilsson Remahl AIM. Infectious and inflammatory disorders might increase the risk of developing idiopathic intracranial hypertension - a national case-control study. Cephalalgia 2020; 40 (10) 1084-1094
• 14 Chuang TY, Burda K, Teklemariam E, Athar K. Tolosa-Hunt syndrome presenting after COVID-19 vaccination. Cureus 2021; 13 (07) e16791
• 15 Oo WM, Giri P, de Souza A. AstraZeneca COVID-19 vaccine and Guillain- Barré syndrome in Tasmania: a causal link?. J Neuroimmunol 2021; 360: 577719
• 16 Khan E, Shrestha AK, Colantonio MA, Liberio RN, Sriwastava S. Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature. J Neurol 2022; 269 (03) 1121-1132
• 17 Rosenblum HG, Hadler SC, Moulia D. et al. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices - United States, July 2021. MMWR Morb Mortal Wkly Rep 2021; 70 (32) 1094-1099
• 18 Goss AL, Samudralwar RD, Das RR, Nath A. ANA Investigates. ANA investigates: neurological complications of COVID-19 vaccines. Ann Neurol 2021; 89 (05) 856-857
• 19 Leber HM, Sant'Ana L, Konichi da Silva NR. et al. Acute thyroiditis and bilateral optic neuritis following SARS-CoV-2 vaccination with Coronavac: a case report. Ocul Immunol Inflamm 2021; 29 (06) 1200-1206
• 20 Thunstedt DC, Straube A, Schöberl F. Isolated intracranial hypertension following COVID-19 vaccination: A case report. Cephalalgia Reports 2021;
• 21 Becker AE, Chiotos K, McGuire JL, Bruins BB, Alcamo AM. Intracranial hypertension in multisystem inflammatory syndrome in children. J Pediatr 2021; 233: 263-267
• 22 Naranjo CA, Busto U, Sellers EM. et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (02) 239-245